Amelioration of persistent left ventricular function impairment through increased plasma ascorbate levels following

Nicolás Valls1, Juan G Gormaz1, Rubén Aguayo2

  • 1a Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile , Santiago , Chile.

Insights

High plasma ascorbate levels significantly improved heart function and microvascular repair after percutaneous coronary angioplasty (PCA) for acute myocardial infarction (AMI). This suggests vitamin C offers protection against reperfusion injury.

Area of Science:

  • Cardiology
  • Biochemistry
  • Oxidative Stress Research

Background:

  • Percutaneous coronary angioplasty (PCA) improves outcomes for acute myocardial infarction (AMI) but can cause myocardial reperfusion injury.
  • Oxidative stress is implicated in the mechanism of reperfusion injury.

Purpose of the Study:

  • To investigate if high plasma ascorbate (vitamin C) levels can mitigate reperfusion injury following successful PCA.
  • To assess the impact of ascorbate levels on left ventricular ejection fraction (LVEF) and microvascular function post-PCA.

Main Methods:

  • Patients with ST-segment elevation myocardial infarction undergoing primary PCA were enrolled.
  • Ascorbate was administered intravenously before reperfusion, followed by oral vitamin C and E supplementation.
  • Left ventricular ejection fraction (LVEF) and Thrombolysis In Myocardial Infarction (TIMI) myocardial perfusion grade (TMPG) were assessed.

Main Results:

  • Patients with high plasma ascorbate (HA group) showed significantly higher LVEF on day 84 compared to the low ascorbate (LA) group (33% increase).
  • Microvascular function improved in the HA group, with 95% achieving a TMPG of 2-3 versus 79% in the LA group.

Conclusions:

  • High plasma ascorbate levels demonstrate a protective effect against oxidative stress during reperfusion injury in PCA patients.
  • These findings support the antioxidant benefits of vitamin C in mitigating cardiac damage after AMI treatment.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
681
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
754
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
485
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
599